Updated Clinical Results from REVLIMID® Continuous Treatment Phase III Study Show Statistically Significant ...
Celgene International Sàrl announced that data from the planned second interim analysis of a phase III, randomised, double-blind study of continuous REVLIMID® for the treatment of patients 65 years or older with newly diagnosed multiple myeloma show a clinically significant improvement in progression-free survival , the primary endpoint of the study.
Read more on Business Wire via Yahoo! Finance
Orignal From: Updated Clinical Results from REVLIMID® Continuous Treatment Phase III Study Show Statistically Significant ...
Post a Comment